BOULDER, Colo.--(BUSINESS WIRE)--Array BioPharma Inc. (NASDAQ: ARRY) announced that it has elected Gwen A. Fyfe, M.D., to its Board of Directors. Dr. Fyfe is an oncology biotechnology veteran with more than 20 years of drug development experience.
“We are thrilled to have a person of Gwen’s caliber join the Array Board. She is an industry leader with an excellent track record of clinical success,” said Kyle Lefkoff, Executive Chairman. “Gwen’s expertise and leadership in advancing cancer therapeutics, including Rituxan®, Herceptin®, Avastin® and Tarceva®, make her an ideal addition to our Board of Directors. We look forward to her contributions.”
“We are thrilled to have a person of Gwen’s caliber join the Array Board. She is an industry leader with an excellent track record of clinical success,” said Kyle Lefkoff, Executive Chairman. “Gwen’s expertise and leadership in advancing cancer therapeutics, including Rituxan®, Herceptin®, Avastin® and Tarceva®, make her an ideal addition to our Board of Directors. We look forward to her contributions.”
